From the Editor:
November 11, 2015
I am pleased to give you and update of the status of our society's journal, Cardiovascular Pathology.
On our CVP journal web site you will find the following metrics:
Source Normalized Impact per Paper (SNIP): 2013: 0.897 - SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field;
SCImago Journal Rank (SJR):2013: 0.802 - SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal's impact.
Impact Factor: 2013: 2.000 - The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
Five-Year Impact Factor: 2013: 2.132 - To calculate the five year Impact Factor, citations are counted in 2014 to the previous five years and divided by the source items published in the previous five years. © Journal Citation Reports 2015, Published by Thomson Reuters.
The most recognized of these metrics is the standard or two year Impact Factor. The recent trend of our CVP two year impact factor is: 1.881 for 2010, 2.066 for 2011, 2.352 for 2012, 2.336 for 2013 and 2.000 for 2014.
While our impact factor remains quite competitive for a clinical subspecialty journal, I have wanted to explore factors that might explain the decrease in our IF for 2014. I discussed this with our Elsevier publisher, Jason Winkler. He suggested the interesting hypothesis that our journal's IF may be significantly influenced by variation in the number of review articles published in the previous two years.
"According to Scopus, there was a spike in review articles published in CVP in 2011 which has declined until 2015 (see chart). Because the 2013 impact factor included citations to articles published in 2011 and 2012, it included the citations to review articles. The 2014 impact factor includes citations to articles in 2012 and 2013. Thus, there were fewer review articles in the calculation for 2014." "Also, drilling down in the Scopus data, there were 56 uncited articles that contributed to the 2013 impact factor and 66 uncited articles contributing to the 2014 impact factor." There was a nearly equal distribution of full length and short communications that contributed to the uncited articles.
The logical conclusion is that a combination of fewer review articles and more uncited articles in a preceding two year period will lower the two-year IF compared to the previous IF. The obvious correlative strategies are to publish more insightful review articles on interesting topics as well as more novel original articles that have a high probability of being cited by other investigators. While these strategies for competing in the arena of journal prestige are clear, the successful implementation remains a challenge for the Editor and the Editorial Board.
Also, it is important to understand that the IF and the other metrics cited above measure the status of a journal and not the impact of the work of individual investigators. Other metrics are used for the latter analysis, including the Hirsh (h) index. According to Wikipedia, the definition of the h index is that a scholar with an index of h has published h papers each of which has been cited in other papers at least h times. Thus, the h-index reflects both the number of publications and the number of citations per publication. The index is designed to improve upon simpler measures such as the total number of citations or publications. The index works properly only for comparing scientists working in the same field; citation conventions differ widely among different fields. I have accessed my own h factor through the Elsevier Scopus/SciVal system. The h factor also can be accessed through Thompson Reuter Web of Science and Google (although the latter is probably less reliable). Other systems such as Research Gate have their own metrics for individual authors. I recommend you seek out your h index.
With the publication of the January-February 2016 issue we will celebrate 25 years of active publication of Cardiovascular Pathology (CVP), the official journal of our Society for Cardiovascular Pathology (SCVP). For this issue, I have written an editorial providing a perspective on our journal featuring an analysis of the content we have published over the last 24 years. In order to commemorate and celebrate twenty five years of publication of CVP, we plan to publish in several upcoming issues of the journal a special series of review articles under the general title of Pathobiology of Cardiovascular Diseases: Past, Present and Future Perspectives. These articles by leading cardiovascular pathologists are intended to provide perspective on major cardiovascular diseases gained from major research contributions over the last twenty five years and insights into future directions in the field
Also we have recently posted new Guidelines for Authors (GFA): (http://www.cardiovascularpathology.com/content/authorinfo). The revised GFA has more appropriate guidelines for the length and numbers of references for the different types of manuscripts. Authors have the option of the traditional publication route or Open Access, but both will have the same peer review. Based on our new contract with Elsevier, the cost for print publication of color figures has been reduced from $650 for the first multi-panel figure and $100 for each subsequent multi-panel figure to $300 and $50 respectively. (There is no charge for color figures in the articles posted online). Also, Elsevier has introduced three innovative features: AudioSlides, Virtual Microscope and Article-Based Publishing (ABP). The latter will be discussed further in the front-matter to the January-February 2016 issue of CVP.
I again thank the members of our editorial board, our reviewers, our colleagues at Elsevier and the leaders and members of the Society for Cardiovascular Pathology for your contributions and support of our journal. Please spread the word that CVP is a quality vehicle for publication of novel experimental and insightful clinicopathological studies in the realm of cardiovascular pathobiology.
I wish you a Happy Thanksgiving and winter holiday season.
With best regards,
L. Maximilian Buja, M.D.
Read previous editor pages in the Archives.